Stockscreener 앱 받기
16.05
7.72%
1.15
시간 외 거래:
16.20
0.15
+0.93%
전일 마감가:
$14.90
열려 있는:
$14.52
하루 거래량:
77,727
Relative Volume:
1.44
시가총액:
$870.44M
수익:
-
순이익/손실:
$-143.59M
주가수익비율:
-5.6842
EPS:
-2.8236
순현금흐름:
$-119.47M
1주 성능:
+3.88%
1개월 성능:
-8.44%
6개월 성능:
-23.50%
1년 성능:
-31.93%
1일 변동 폭
$14.52
$17.00
1주일 범위
$14.14
$17.00
52주 변동 폭
$14.14
$26.57
Pharvaris Nv Stock (PHVS) Company Profile
PHVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
16.05 | 870.44M | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-25 | 개시 | Wedbush | Outperform |
| 2023-08-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 개시 | Bryan Garnier | Buy |
| 2022-09-13 | 재개 | JMP Securities | Mkt Outperform |
| 2022-08-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-02 | 개시 | BofA Securities | Neutral |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
모두보기
Pharvaris Nv 주식(PHVS)의 최신 뉴스
Can Pharvaris Impress Investors at Upcoming Leerink Conference? - StockTitan
How to Take Advantage of moves in (PHVS) - Stock Traders Daily
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth - Yahoo Finance
(PHVS) Trading Report - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Sees Significant Increase in Short Interest - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Gap DownWhat's Next? - MarketBeat
(PHVS) Investment Analysis - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Price Target Raised to $55.00 - MarketBeat
Where are the Opportunities in (PHVS) - Stock Traders Daily
Barclays PLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now? - Insider Monkey
FY2026 EPS Estimates for Pharvaris Decreased by Analyst - Defense World
Leerink Partnrs Brokers Cut Earnings Estimates for Pharvaris - MarketBeat
Pharvaris (NASDAQ:PHVS) Trading Up 5.3%What's Next? - MarketBeat
How To Trade (PHVS) - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Stock Price Down 11.7%Here's Why - MarketBeat
Pharvaris Advances Phase 3 HAE Programs, Expands Pipeline Into Acquired Angioedema Treatment - StockTitan
Geode Capital Management LLC Boosts Holdings in Pharvaris (NASDAQ:PHVS) - Defense World
Barclays PLC Takes Position in Pharvaris (NASDAQ:PHVS) - Defense World
(PHVS) Long Term Investment Analysis - Stock Traders Daily
Jane Street Group LLC Makes New Investment in Pharvaris (NASDAQ:PHVS) - Defense World
Jane Street Group LLC Acquires Shares of 28,418 Pharvaris (NASDAQ:PHVS) - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
State Street Corp Purchases New Shares in Pharvaris (NASDAQ:PHVS) - Defense World
53,980 Shares in Pharvaris (NASDAQ:PHVS) Bought by State Street Corp - MarketBeat
Pharvaris (NASDAQ:PHVS) Trading Down 3.5%Here's Why - MarketBeat
Pharvaris: Despite 30% Decline, Still Fair At Best (NASDAQ:PHVS) - Seeking Alpha
Pharvaris (NASDAQ:PHVS) Sees Large Decrease in Short Interest - MarketBeat
Trend Tracker for (PHVS) - Stock Traders Daily
Pharvaris (PHVS) Shares Cross Above 200 DMA - Nasdaq
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $906,000 in Pharvaris (NASDAQ:PHVS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New $906,000 Investment in Pharvaris (NASDAQ:PHVS) - MarketBeat
Learn to Evaluate (PHVS) using the Charts - Stock Traders Daily
Pharvaris (PHVS) Price Target Increased by 38.65% to 32.93 - MSN
Pharvaris price target lowered to $46 from $50 at JMP Securities - Yahoo Finance
Long Term Trading Analysis for (PHVS) - Stock Traders Daily
Pharvaris Reports Q3 2024 Progress and Financials - TipRanks
Pharvaris Reports 93% HAE Attack Reduction in Trial Data, Plans Phase 3 Study | PHVS Stock News - StockTitan
Pharvaris to Present HAE Treatment Progress at Guggenheim Healthcare Conference | PHVS Stock News - StockTitan
PHVS Makes Notable Cross Below Critical Moving Average - Nasdaq
Axonis Therapeutics Announces $115 Million Series A Financing - Financial Times
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting - StockTitan
(PHVS) Proactive Strategies - Stock Traders Daily
Pharvaris Nv (PHVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.14%
2.83%
자본화:
|
볼륨(24시간):